Skip to main content

SLAMF7-CAR T cells prepared by Sleeping Beauty gene-transfer for immunotherapy of multiple myeloma – a rare hematologic disease

Ziel

CARAMBA is proposing to use the revolutionary CAR-T cell technology to tackle multiple myeloma, a rare and incurable hematologic malignancy. Myeloma is associated with a substantial socioeconomic burden and there is a strong demand by patients, their families and caregivers for a curative myeloma treatment. The CARAMBA investigators will conduct a phase I/II clinical trial of immunotherapy with patient-derived T cells that are engineered to express a synthetic chimeric antigen receptor (CAR) specific for the myeloma antigen SLAMF7. SLAMF7 is uniformly expressed on all myeloma cells in every patient, and SLAMF7 CAR-T cells will be equally effective in women and men. The efficacy and safety of SLAMF7 CAR-T cells has been validated by the coordinator in comprehensive pre-clinical testing which highlighted their unprecedented curative potential. SLAMF7 CAR-T cells have received an orphan designation for the indication multiple myeloma by the EC. The successful conduct, rapid and complete recruitment into the clinical trial is ensured by participation of 4 clinical myeloma centres of excellence in 4 EU member states, and the largest myeloma patient advocacy group in Europe, MPE. The SME partners in CARAMBA are prepared to develop the SLAMF7 CAR product all the way to market authorization. CAR-T cell therapy has been recognized as a ‘Breakthrough Therapy’ and clinical proof-of-concept obtained with CD19 CAR-T cells in leukemia and lymphoma. CARAMBA is building on novel and proprietary, cutting-edge CAR technologies including virus-free Sleeping Beauty CAR gene-transfer from DNA minicircles which substantially reduces the cost of CAR-T cell manufacturing, making it an economically viable and sustainable medicinal product. We are confident, that if funded, CARAMBA will accomplish its objective to establish the role of CAR-T cell therapy as a therapeutically effective, commercially attractive and socioeconomically desirable treatment in myeloma and other rare diseases.

Aufforderung zur Vorschlagseinreichung

H2020-SC1-2017-Two-Stage-RTD
Andere Projekte für diesen Aufruf anzeigen

Koordinator

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUS-MAXIMILIANS-UNIVERSITAT
Adresse
Josef-schneider-strasse 2
97080 Wurzburg
Deutschland
Aktivitätstyp
Higher or Secondary Education Establishments
EU-Beitrag
€ 2 051 250

Beteiligte (10)

OSPEDALE SAN RAFFAELE SRL
Italien
EU-Beitrag
€ 893 125
Adresse
Via Olgettina 60
20132 Milano
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
UNIVERSIDAD DE NAVARRA
Spanien
EU-Beitrag
€ 624 375
Adresse
Campus Universitario Edificio Central
31080 Pamplona
Aktivitätstyp
Higher or Secondary Education Establishments
CENTRE HOSPITALIER REGIONAL ET UNIVERSITAIRE DE LILLE
Frankreich
EU-Beitrag
€ 384 375
Adresse
Avenue Oscar Lambret 2
59037 Lille
Aktivitätstyp
Higher or Secondary Education Establishments
BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
Deutschland
EU-Beitrag
€ 342 875
Adresse
Paul-ehrlich-strasse 51-59
63225 Langen
Aktivitätstyp
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
DRK-BLUTSPENDEDIENST BADEN-WURTTEMBERG-HESSEN GGMBH
Deutschland
EU-Beitrag
€ 685 000
Adresse
Friedrich Ebert Strasse 107
68167 Mannheim
Aktivitätstyp
Research Organisations
MYELOMA PATIENTS EUROPE AISBL
Belgien
EU-Beitrag
€ 115 625
Adresse
Avenue Louise 143 4
1050 Bruxelles
Aktivitätstyp
Other
NBE-THERAPEUTICS AG
Schweiz
EU-Beitrag
€ 170 000
Adresse
Hochbergerstrasse 60C Technologie Park Basel
4057 Basel
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
T-CURX GMBH
Deutschland
EU-Beitrag
€ 503 750
Adresse
Friedrich-bergius-ring 15
97076 Wurzburg
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC
Frankreich
EU-Beitrag
€ 152 493,74
Adresse
Rue Du Dessous Des Berges 58A
75013 Paris
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
ARTTIC INNOVATION GMBH
Deutschland
EU-Beitrag
€ 175 006,26
Adresse
Oskar-von-miller-ring 29
80333 Munchen
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)